Shepherd and Wedderburn has acted for Spero Oncology Ltd in its recent sale to Veristat International.
UK-based Spero Oncology is a Clinical Research Organisation (CRO) specialising in the provision of oncology drug development consultancy, feasibility studies and early phase oncology trials primarily throughout Europe, but also in Australia and New Zealand.
As a result of the sale, Spero Oncology has become part of Veristat International, a US-based full-service CRO with over 20 years’ experience in supporting clinical trials and regulatory submissions for pharmaceutical, biotechnology and medical device companies in the US and Canada.